{"nctId":"NCT00184600","briefTitle":"Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes","startDateStruct":{"date":"2004-11"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":708,"armGroups":[{"label":"Insulin detemir (basal insulin)","type":"EXPERIMENTAL","interventionNames":["Drug: insulin detemir"]},{"label":"Insulin aspart (prandial insulin)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: biphasic insulin aspart"]},{"label":"Biphasic insulin aspart 30 (biphasic insulin)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: insulin aspart"]}],"interventions":[{"name":"biphasic insulin aspart","otherNames":[]},{"name":"insulin detemir","otherNames":[]},{"name":"insulin aspart","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes\n* Insulin naive\n* On OAD treatment for at least 4 months with metformin, a sulphonylurea or a combination\n* Body Mass Index (BMI) below or equal to 40.0 kg/m2\n* HbA1c (glycosylated haemoglobin): 7.0%-10% (both inclusive)\n\nExclusion Criteria:\n\n* Proliferative retinopathy\n* Recurrent major hypoglycaemia\n* Cardial problems\n* Uncontrolled hypertension\n* Impaired hepatic or renal function","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"HbA1c (Glycosylated Haemoglobin) at Month 12","description":"HbA1c values offer evidence of the efficacy and durability of the insulin regimens.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.45","spread":"0.80"},{"groupId":"OG001","value":"8.55","spread":"0.78"},{"groupId":"OG002","value":"8.63","spread":"0.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.64","spread":"0.96"},{"groupId":"OG001","value":"7.20","spread":"1.06"},{"groupId":"OG002","value":"7.33","spread":"0.95"}]}]}]},{"type":"PRIMARY","title":"HbA1c (Glycosylated Haemoglobin) at Month 36","description":"HbA1c values offer evidence of the efficacy and durability of the insulin regimens.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.45","spread":"0.80"},{"groupId":"OG001","value":"8.55","spread":"0.78"},{"groupId":"OG002","value":"8.63","spread":"0.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.11","spread":"1.13"},{"groupId":"OG001","value":"7.04","spread":"1.17"},{"groupId":"OG002","value":"7.22","spread":"1.11"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants (Total Participants and the Subset of Participants Who Did Not Have an Hypoglycaemic Episode) Achieving a Month 12 Value in HbA1c Below or Equal to 6.5%","description":"Two participant counts are listed. The first is the percentage of total participants who achieved the target (HbA1c below or equal to 6.5%) at Month 12. The second is the percentage of subset of participants who achieved the target and did not have either minor or major hypoglycaemic episode within the four weeks prior to the month 12 exam. Minor hypoglycaemic episode is an episode in which the participant was able to treat her/himself and plasma glucose was below 3.1 mmol/L (56 mg/dL). Major hypoglycaemic episode is an episode in which the participant was unable to treat her/himself.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null},{"groupId":"OG001","value":"23.9","spread":null},{"groupId":"OG002","value":"17.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.9","spread":null},{"groupId":"OG001","value":"43.9","spread":null},{"groupId":"OG002","value":"52.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Month 36 Value in HbA1c Below or Equal to 6.5%","description":"Percentage of participants who achieved the target (HbA1c below or equal to 6.5%) at Month 36","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.2","spread":null},{"groupId":"OG001","value":"44.8","spread":null},{"groupId":"OG002","value":"31.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Hypoglycaemic Events Per Participant Per Year at Month 12 for All Participants and the Subset Who Achieved Target HbA1c Below or Equal to 6.5%","description":"Rate of hypoglycaemic events was calculated as the median number of events per participant per year, defined as grade 1 (symptoms only), 2 (minor) and 3 (major). Symptoms only if self-measured plasma glucose level of 3.1 mmol/L (56 mg/dL) or more. Minor (grade 2) if able to treat her/himself and plasma glucose was below 3.1 mmol/L (56 mg/dL). Major (grade 3) if unable to treat her/himself. Rates are reported for all participants and for the subset of participants who achieved target HbA1c below or equal to 6.5%.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"8.0","spread":null},{"groupId":"OG002","value":"5.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"8.0","spread":null},{"groupId":"OG002","value":"3.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"8.0","spread":null},{"groupId":"OG002","value":"3.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":null},{"groupId":"OG001","value":"7.8","spread":null},{"groupId":"OG002","value":"5.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null},{"groupId":"OG001","value":"8.0","spread":null},{"groupId":"OG002","value":"4.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null},{"groupId":"OG001","value":"8.7","spread":null},{"groupId":"OG002","value":"4.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Hypoglycaemic Events Per Participant Per Year at Month 36 for All Participants and the Subset Who Achieved Target HbA1c Below or Equal to 6.5%","description":"Rate of hypoglycaemic events was calculated as the median number of events per participant per year, defined as grade 1 (symptoms only), 2 (minor) and 3 (major). Symptoms only if self-measured plasma glucose level of 3.1 mmol/L (56 mg/dL) or more. Minor (grade 2) if able to treat her/himself and plasma glucose was below 3.1 mmol/L (56 mg/dL). Major (grade 3) if unable to treat her/himself. Rates are reported for all participants and for the subset of participants who achieved target HbA1c below or equal to 6.5%.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"5.7","spread":null},{"groupId":"OG002","value":"3.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null},{"groupId":"OG001","value":"5.5","spread":null},{"groupId":"OG002","value":"3.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null},{"groupId":"OG001","value":"5.7","spread":null},{"groupId":"OG002","value":"3.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null},{"groupId":"OG001","value":"5.7","spread":null},{"groupId":"OG002","value":"3.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"5.3","spread":null},{"groupId":"OG002","value":"2.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"5.5","spread":null},{"groupId":"OG002","value":"3.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Required A Second Insulin Therapy by Month 12","description":"Percentage of participants who required a second insulin formulation to be added to their treatment. This outcome offers evidence to the efficacy and durability of the insulin regimens.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.9","spread":null},{"groupId":"OG001","value":"4.2","spread":null},{"groupId":"OG002","value":"8.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Required A Second Insulin Therapy by Month 36","description":"Percentage of participants who required a second insulin formulation to be added to their treatment. This outcome offers evidence to the efficacy and durability of the insulin regimens.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"88","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight at Month 12","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"4.2"},{"groupId":"OG001","value":"5.7","spread":"4.6"},{"groupId":"OG002","value":"4.7","spread":"4.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight at Month 36","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"0.5"},{"groupId":"OG001","value":"6.4","spread":"0.5"},{"groupId":"OG002","value":"5.7","spread":"0.5"}]}]}]},{"type":"SECONDARY","title":"Change in Eight-point Capillary Plasma Glucose Profiles (Self-measured) at 12 Months","description":"For each visit and telephone contact, participants were asked to perform in advance three capillary glucose profiles (using blood glucose metre provided for the trial) obtained before breakfast and before the evening meal for participants in the biphasic and basal groups and before meals and two hours after meals and at bedtime in the prandial group.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-43","spread":"43"},{"groupId":"OG001","value":"-65","spread":"43"},{"groupId":"OG002","value":"-59","spread":"54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-59","spread":"52"},{"groupId":"OG001","value":"-23","spread":"49"},{"groupId":"OG002","value":"-45","spread":"56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-47","spread":"54"},{"groupId":"OG001","value":"-83","spread":"54"},{"groupId":"OG002","value":"-68","spread":"63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-40","spread":"70"},{"groupId":"OG001","value":"-34","spread":"59"},{"groupId":"OG002","value":"-52","spread":"70"}]}]}]},{"type":"SECONDARY","title":"Change in Eight-point Capillary Plasma Glucose Profiles (Self-measured) at 36 Months","description":"For each visit and telephone contact, participants were asked to perform in advance three capillary glucose profiles (using blood glucose metre provided for the trial) obtained before breakfast and before the evening meal for participants in the biphasic and basal groups and before meals and two hours after meals and at bedtime in the prandial group.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-58","spread":"43"},{"groupId":"OG001","value":"-67","spread":"47"},{"groupId":"OG002","value":"-56","spread":"47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-47","spread":"49"},{"groupId":"OG001","value":"-49","spread":"45"},{"groupId":"OG002","value":"-50","spread":"47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-67","spread":"50"},{"groupId":"OG001","value":"-85","spread":"59"},{"groupId":"OG002","value":"-61","spread":"58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-45","spread":"77"},{"groupId":"OG001","value":"-27","spread":"70"},{"groupId":"OG002","value":"-38","spread":"77"}]}]}]},{"type":"SECONDARY","title":"Quality of Life as Measured by the EuroQol Group 5-Dimension Self-Report Questionnaire Score (EQ5D) at 12 Months","description":"The EuroQol Group 5-Dimension Self-Report Questionnaire score (EQ5D) is a standardised instrument for use as a measure of health outcome in medical research. Responses can be used to generate a single numerical value associated with a given health state. The scale of values is graded from -0.59 to 1.00, with lower scores indicating a poorer health status. A score of 0 represents no quality of life and scores less than 0 represent states perceived by the respondent to be worse than death.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.78","spread":null},{"groupId":"OG001","value":"0.76","spread":null},{"groupId":"OG002","value":"0.76","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Life as Measured by the EuroQol Group 5-Dimension Self-Report Questionnaire Score (EQ5D) at 36 Months","description":"The EuroQol Group 5-Dimension Self-Report Questionnaire score (EQ5D) is a standardised instrument for use as a measure of health outcome in medical research. Responses can be used to generate a single numerical value associated with a given health state. The scale of values is graded from -0.59 to 1.00, with lower scores indicating a poorer health status. A score of 0 represents no quality of life and scores less than 0 represent states perceived by the respondent to be worse than death.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.80","spread":null},{"groupId":"OG001","value":"0.77","spread":null},{"groupId":"OG002","value":"0.76","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Having an 'Other' Adverse Event","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"227","spread":null},{"groupId":"OG001","value":"235","spread":null},{"groupId":"OG002","value":"228","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":78,"n":234},"commonTop":["Nasopharyngitis","Infection","Diarrhoea","Cough","Vomiting"]}}}